Literature DB >> 33976473

Databases for technical aspects of immunohistochemistry: 2021 update.

Takayasu Moroki^1,2, Saori Matsuo^1,3, Hirofumi Hatakeyama^1,4, Seigo Hayashi^1,5, Izumi Matsumoto^1,6, Satoshi Suzuki^1,7, Takashi Kotera^1,8, Kazuyoshi Kumagai^1,9, Kiyokazu Ozaki^1,1.

Abstract

With the aim of sharing information about the technical aspects of immunohistochemistry (IHC) and facilitating the selection of suitable antibodies for histopathological examination, this technical report describes the results of a questionnaire distributed during the period of 2018 to 2019 among members of the Conference on Experimental Animal Histopathology. Additionally, it describes the immunological properties and supplier details (clone, supplier, catalog number, species reactivity, etc.) as well as the IHC staining conditions (fixing solution, fixing time, embedding, antigen retrieval method, antibody dilution, incubation time, incubation temperature, positive control tissue, blocking condition, secondary antibody information, etc.) for a total of 509 primary antibodies (comprising 220 different types). These survey results were an update on the contents reported by CEAH in 2017. ©2021 The Japanese Society of Toxicologic Pathology.

Entities: CellLine Chemical Disease Gene Mutation Species

Keywords: antibody; experimental animal; immunohistochemistry; toxicological pathology

Year: 2021 PMID： 33976473 PMCID： PMC8100252 DOI： 10.1293/tox.2021-0006

Source DB: PubMed Journal: J Toxicol Pathol ISSN： 0914-9198 Impact factor: 1.628

Immunohistochemistry (IHC) is a biochemical method that involves the utilization of an antibody-based strategy for identifying a specific antigen, in order to understand the distribution as well as localization of biomarkers and differentially expressed proteins in different regions of a biological tissue[1]. IHC is widely used for diagnostic interpretation and understanding of pathogenesis, whereby it has become a routine tool for toxicological pathology. In 2017 (survey period: 2014 to 2015), the IHC database summarized various IHC staining conditions, as reported by the Conference on Experimental Animal Histopathology (CEAH), which includes 89 research institutes—such as pharmaceutical companies, chemical companies, universities, public research institutes, and contract research organizations—involved in experimental animal pathological research in Japan and Korea[2]. Since the IHC database is of particular significance to pathologists, it is important to provide the latest information on IHC and to revise the discontinued antibodies or changes in supplier name. Therefore, a questionnaire about IHC was distributed during the period of 2018 to 2019 among members of the CEAH, and the database was updated based on its results. In addition, blocking condition information has been added to this updated database. A total of 509 primary antibodies (comprising 220 different types) were available from 62 research institutes, according to the responses to the questionnaire. With the aim of sharing information about the technical aspects of IHC and facilitating the selection of suitable antibodies for histopathological examination, the present technical report describes the IHC questionnaire results. Moreover, the IHC histological photographs of some primary antibodies have been provided in the figures to clarify the antigen localization and staining conditions in the respective tissues. The immunological properties and supplier details of primary antibodies (clone, supplier, catalog number, species reactivity, etc.), as well as IHC staining conditions (fixing solution, fixing time, embedding, antigen retrieval method, antibody dilution, incubation time, incubation temperature, positive control tissue, blocking condition, secondary antibody information, etc.) are presented in Table 1, 2, 3, 4, 5, 6, 7, 8, 9. and Supplementary Table 1–12: online only, while Fig. Fig. 1, Fig. 2, Fig. 3, Fig. 4, Fig. 5, Fig. 6, Fig. 7, Fig. 8, Fig. 9, Fig. 10, Fig. 11, Fig. 12, Fig. 13, Fig. 14, Fig. 15, Fig. 16, Fig. 17, Fig. 18, Fig. 19, Fig. 20, Fig. 21, Fig. 22, Fig. 23, Fig. 24, Fig. 25, Fig. 26, Fig. 27, Fig. 28, Fig. 29, Fig. 30, Fig. 31, Fig. 32, Fig. 33, Fig. 34, Fig. 35, Fig. 36, Fig. 37, Fig. 38, Fig. 39, Fig. 40, Fig. 41, Fig. 42, Fig. 43, Fig. 44, Fig. 45, Fig. 46, Fig. 47, Fig. 48, Fig. 49, Fig. 50, Fig. 51, Fig. 52, Fig. 53, Fig. 54, Fig. 55, Fig. 56, Fig. 57, Fig. 58, Fig. 59, Fig. 60, Fig. 61, Fig. 62, Fig. 63, Fig. 64, Fig. 65, Fig. 66, Fig. 67, Fig. 68, Fig. 69, Fig. 70, Fig. 71, Fig. 72, Fig. 73, Fig. 74, Fig. 75, Fig. 76, Fig. 77, Fig. 78, Fig. 79, Fig. 80, Fig. 81, Fig. 82, Fig. 83, Fig. 84, Fig. 85, Fig. 86, Fig. 87, Fig. 88, Fig. 89, Fig. 90, Fig. 91, Fig. 92, Fig. 93, Fig. 94, Fig. 95, Fig. 96, Fig. 97, Fig. 98, Fig. 99, Fig. 100, Fig. 101, Fig. 102, Fig. 103, Fig. 104, Fig. 105, Fig. 106, Fig. 107, Fig. 108, Fig. 109, Fig. 110, Fig. 111, Fig. 112, Fig. 113, Fig. 114, Fig. 115, Fig. 116, Fig. 117, Fig. 118, Fig. 119, Fig. 120, Fig. 121, Fig. 122, Fig. 123, Fig. 124, Fig. 125, Fig. 126, Fig. 127, Fig. 128, Fig. 129, Fig. 130, Fig. 131, Fig. 132, Fig. 133, Fig. 134, Fig. 135, Fig. 136 depict IHC histological photographs.

Table 1.